We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News > Psychedelics > Content Piece

Awakn Expands Its Ketamine Trial For Alcohol Use Disorder

By Leo Bear-McGuinness

Published: Dec 13, 2022   

Complete the form below and we will email you a PDF version of "Awakn Expands Its Ketamine Trial For Alcohol Use Disorder"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A first-of-its-kind phase 3 trial will soon begin in the UK to test whether ketamine can help treat patients with alcohol use disorder (AUD).

The study will take place across seven sites in the UK, all run by the country’s National Health Service (NHS), and will be partly funded by a grant from the National Institute for Health and Care Research (NIHR), a UK government agency.

The rest of the funding will be provided by Awakn, the biotechnology company spearheading the study.

Ketamine, not cocktails

Despite the adverse medical and economic harms associated with AUD, few patients receive medication to treat their disorder. And these medications are limited; no new compounds for treating AUD have been approved by the US Food and Drug Administration (FDA) since 2004.

In an attempt to provide a new, effective treatment, Awakn has partnered with the University of Exeter’s Celia Morgan, a professor of psychopharmacology, to test the potential benefits ketamine-assisted therapy could offer AUD patients.

“More than two million UK adults have serious alcohol problems, yet only one in five of those get treatment,” Morgan said in a statement.

“Unfortunately, three out of four people who quit alcohol will be back drinking heavily after a year. Alcohol-related harm is estimated to cost the NHS around £3.5 billion each year, and wider UK society around £40 billion. Alcohol problems affect not only the individual but families, friends and communities, and related deaths have increased still further since the pandemic. We urgently need new treatments. If this trial definitively establishes that ketamine and therapy works, we hope we can begin to see it used in NHS settings.”

Morgan aims to recruit 280 patients with AUD for the trial. These participants will be randomly allocated into two groups. Half will be given ketamine and receive psychological therapy. The other half will be given a very low dose of ketamine and a seven-session education package about the harmful effects of alcohol.

The trial follows on from its phase 2 predecessor – also led by Professor Morgan – which resulted in its participants experiencing an average 86% abstinence rate six months on from treatment; abstinence rates were, on average, 2% prior to the trial.

The phase three trial will focus on establishing “further definitive evidence” of ketamine’s efficacy and move towards the novel treatment being licensed for this indication, according to Awakn.

It is expected to be the largest ketamine-assisted therapy clinical trial to date and the only phase three psychedelic clinical trial ever to receive government funding. “For this phase III to have the support and funding from the NIHR and for it to be delivered in the NHS is a great endorsement of this treatment’s potential and a sign of how badly a new more effective treatment is needed to help the millions of people suffering from Alcohol addiction in the UK,” Anthony Tennyson, Awakn’s CEO, said in a statement.

“We are very proud to be part of this important piece of work. With two Awakn clinics already open in the UK and more in Europe we are already seeing the incredible benefits of this treatment for our clients on an off-label basis.”

Awakn’s work

Awakn’s belief in the powers of ketamine extends beyond AUD; the company has also run trials to see whether the drug can help treat gambling addiction, binge eating disorder, compulsive sexual behavior, and internet gaming disorder.

Speaking to Analytical Cannabis last year on Awakn’s gambling disorder study, Professor Morgan – who ran this trial, too – explained the study’s design and why her team aimed to test ketamine’s potential as a behavior-disrupting drug.

“We are using one of the capacities of the ketamine which is to block a process of re-stabilization of memory. In the study that we’re doing, we’re going to reactivate gambling memories. We’ll be showing people, depending on what their modality of gambling is, a roulette wheel or slot machines or horses, and this reactivates the memory,” she said.

“Normally in memory, this means that this memory becomes active and you’re able to update it. Then it’s restabilized – saved again, in computer terms – and is laid down more strongly. If you give ketamine during this time of reactivation, what’s been found particularly in animals is that this can weaken the memory trace. That’s what we’re looking at in this study.”

 

Like what you just read? You can find similar content on the topic tags shown below.

Science & Health Psychedelics

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement